Because Patients Can’t Wait, BioNJ is actively engaged in advocating for and communicating with the life sciences industry in New Jersey and beyond. BioNJ is focused on addressing issues and programs with members of New Jersey’s congressional delegation in Washington and in Trenton with the Christie Administration and the members of the New Jersey State Legislature that can have either a positive or negative impact on the industry.
Throughout 2014, BioNJ has been at the forefront of several legislative initiatives and programs aimed at supporting and helping our Member companies grow both now and in the future including advocating for important amendments to proposed legislation.
As example of public policy in action:
- The BioNJ Team partnered with Rare New Jersey at the 2014 Rare Disease Day alongside the National Organization for Rare Disorders (NORD) at the State House in Trenton this past March to raise awareness about the need to treat rare disorders.
- BioNJ is a leader in a coalition advocating to ensure that legislation regulating the prescribing and dispensation of biosimilars will have rules facilitating patient-physician-pharmacist communication and the creation and safekeeping of accurate medical records.
- BioNJ partnered with Rutgers University on the development of a clinical trials Master Service Agreement (MSA) which is designed to expedite the negotiation time for translation studies being conducted at New Jersey institutions.
- At the federal level, we continue to advocate for measures that protect Medicare Parts B and D and support medical innovation through increased funding for the FDA and NIH. BioNJ attended a number of important programs in Washington, including the BIO Fly-In in May, as well as the We Work For Health 2014 Co-Chair Summit in July where members of our Team with members of the Congressional delegation.